← Back to Screener
MAIA Biotechnology, Inc. (MAIA)
Price$1.30
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)43.66%
Price vs S&P 500 (4W)-1.24%
VGM Score42.44
Market Capitalization$84.51M
All Metrics
Book Value / Share (Quarterly)$0.46
P/TBV (Annual)2.13x
Cash Flow / Share (Quarterly)$-0.33
Price vs S&P 500 (YTD)-20.08%
EPS (TTM)$-0.68
10-Day Avg Trading Volume0.52M
EPS Excl Extra (TTM)$-0.68
EPS (Annual)$-0.70
ROI (Annual)-942.66%
Cash / Share (Quarterly)$0.57
ROA (Last FY)-230.78%
EBITD / Share (TTM)$-0.71
ROE (5Y Avg)-1208.97%
Cash Flow / Share (Annual)$-0.49
P/B Ratio3.04x
P/B Ratio (Quarterly)3.06x
Net Income / Employee (Annual)$-1,722,800
Net Interest Coverage (TTM)-3091.02x
ROA (TTM)-142.94%
EPS Incl Extra (Annual)$-0.70
Current Ratio (Annual)1.66x
Quick Ratio (Quarterly)5.44x
3-Month Avg Trading Volume0.88M
52-Week Price Return-23.20%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.20
52-Week High$3.19
EPS Excl Extra (Annual)$-0.70
26-Week Price Return59.59%
Quick Ratio (Annual)1.48x
13-Week Price Return-36.24%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.59x
Enterprise Value$50.10M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.22
3-Month Return Std Dev80.44%
Net Income / Employee (TTM)$-1,865,300
ROE (Last FY)-942.66%
Net Interest Coverage (Annual)-1441.91x
EPS Basic Excl Extra (Annual)$-0.70
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.68
ROI (TTM)-284.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.78
Price vs S&P 500 (52W)-51.41%
Year-to-Date Return-9.15%
5-Day Price Return8.59%
EPS Normalized (Annual)$-0.70
ROA (5Y Avg)-192.53%
Month-to-Date Return4.51%
EBITD / Share (Annual)$-0.76
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-1208.97%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.68
P/TBV (Quarterly)6.60x
P/B Ratio (Annual)23.85x
Book Value / Share (Annual)$0.06
Price vs S&P 500 (13W)-45.98%
Beta0.24x
Revenue / Share (TTM)$0.00
ROE (TTM)-284.80%
52-Week Low$0.87
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.14est. -0.18
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MAIAMAIA Biotechnology, Inc. | — | — | C | $1.30 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing THIO, an investigational drug candidate with dual anti-cancer mechanisms targeting telomeres and immune function. The lead program combines THIO with Regeneron's approved checkpoint inhibitor Libtayo (cemiplimab) to treat patients with advanced non-small cell lung cancer. The combination approach aims to enhance the immune system's ability to attack cancer cells.